A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Latest Information Update: 04 Jun 2024
At a glance
- Drugs Ozanimod (Primary) ; Interferon beta-1a
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms SUNBEAM
- Sponsors Celgene Corporation; Celgene International SARL; Receptos
- 18 Apr 2024 Updated findings from the Phase 3 SUNBEAM and DAYBREAK Extension Trials presented at the 76th Annual Meeting of the American Academy of Neurology 2024
- 18 Apr 2024 Results of absolute lymphocyte count (ALC) ,from NCT02294058 and NCT02047734 presented at the 76th Annual Meeting of the American Academy of Neurology 2024.
- 02 Mar 2024 Updated findings from the Phase 3 SUNBEAM and DAYBREAK Extension Trials presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024